Active surveillance is noninferior to BCG induction therapy for invasive relapse-free survival in patients with high-grade T1 bladder cancer with no residual tumor on second TURBT. For patients with ...
OSLO, Norway, March 16, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results